Robert Vanhimbergen Buys 4,200 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CFO Robert Vanhimbergen bought 4,200 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $23.08 per share, with a total value of $96,936.00. Following the completion of the purchase, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. The trade was a 3.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Elanco Animal Health Trading Up 2.0%

Elanco Animal Health stock opened at $22.73 on Wednesday. The stock has a 50-day simple moving average of $24.65 and a 200 day simple moving average of $24.06. The stock has a market capitalization of $11.36 billion, a P/E ratio of -55.44, a PEG ratio of 1.33 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.10 and a current ratio of 2.05. Elanco Animal Health Incorporated has a 52 week low of $17.08 and a 52 week high of $27.98.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same quarter in the prior year, the company earned $0.26 earnings per share. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. NewEdge Advisors LLC increased its position in Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in shares of Elanco Animal Health in the second quarter valued at about $38,000. Root Financial Partners LLC boosted its position in shares of Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares during the period. Uniplan Investment Counsel Inc. acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at about $41,000. Finally, Torren Management LLC acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at about $46,000. 97.48% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ELAN shares. KeyCorp raised their price target on Elanco Animal Health from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Morgan Stanley upped their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 22nd. UBS Group increased their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Citigroup lifted their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, TD Cowen upped their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.